COMMUNIQUÉS West-GlobeNewswire
-
UPDATE - Lumina Therapy Alliance Expands National Footprint with Addition of The Therapy Group of DC, Reaching Nearly 400 Clinicians Nationwide
31/03/2026 -
Jupiter Neurosciences to Present at Emerging Growth Conference on April 2
31/03/2026 -
BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis
31/03/2026 -
Fagron increases share capital through exercise subscription rights
31/03/2026 -
Serenity Medical Receives U.S. FDA HDE Approval of the River™ Stent - the First Venous Stent Approved for Severe, Refractory Idiopathic Intracranial Hypertension (IIH)
31/03/2026 -
Indiana Overdose Deaths Drop 18% But Deadly New Substances Threaten to Reverse Progress
31/03/2026 -
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
31/03/2026 -
Stage4Hope™ Commits $2.5 Million to Memorial Sloan Kettering Cancer Center to Accelerate Breakthrough Cancer Research
31/03/2026 -
EssilorLuxottica et Meta élargissent leur portefeuille de lunettes IA avec les modèles Ray-Ban Meta optiques
31/03/2026 -
EssilorLuxottica and Meta Expand AI Glasses Portfolio with Ray-Ban Meta Optics Styles
31/03/2026 -
New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
31/03/2026 -
Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026
31/03/2026 -
Global Medtech CDMO Market Grows to $96.5B in 2025 as Pharma-Medtech Convergence Emerges as a Defining Accelerator
31/03/2026 -
TimelyCare Lands Fifth Straight Appearance on Inc. Fastest-Growing Companies in the Southwest list
31/03/2026 -
Alabama Attorney General Steve Marshall Champions The Helios Alliance's Project RenewAL to Advance Statewide Opioid Abatement
31/03/2026 -
Wildfire Smoke is Coming; Millions of Canadian Lungs Aren’t Ready
31/03/2026 -
MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
31/03/2026 -
Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year 2025
31/03/2026 -
Lumina Therapy Alliance Expands National Footprint with Addition of The Therapy Group of DC, Reaching Nearly 400 Clinicians Nationwide
31/03/2026
Pages